12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1. Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2. Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3. Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4. Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2022 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2022-2035
12.2.6.4. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2022-2035
12.2.6.5. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2022-2035
12.2.6.6. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2022-2035
12.2.6.7. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, 2022-2035
12.2.6.8. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2022-2035
12.2.6.9. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2022-2035
12.2.6.10. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2022-2035
12.2.6.11. Next Generation Drug Conjugates Market for Hemophilia, 2022-2035
12.2.6.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2022-2035
12.2.6.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2022-2035
12.2.6.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2022-2035
12.2.6.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2022-2035
12.2.6.16. Next Generation Drug Conjugates Market for Cardiovascular Diseases due to HLP, 2022-2035
12.2.7. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.7.1. Next Generation Drug Conjugates Market in North America, 2022-2035
12.2.7.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.7.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.7.2. Next Generation Drug Conjugates Market in Europe, 2022-2035
12.2.7.2.1. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.7.2.2. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.7.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.7.2.4. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.7.2.5. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.7.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.7.3. Next Generation Drug Conjugates Market in Asia-Pacific, 2022-2035
12.2.7.3.1. Next Generation Drug Conjugates Market in Japan, 2022-2035
12.2.7.3.2. Next Generation Drug Conjugates Market in Australia, 2022-2035
12.2.7.3.3. Next Generation Drug Conjugates Market in Brazil, 2022-2035
12.2.7.4. Next Generation Drug Conjugates Market in Rest of the World, 2022-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2022-2035
12.3.1. Lutathera®
12.3.1.1. Sales Forecast (USD Million)
12.3.2. Pluvicto®
12.3.2.1. Sales Forecast (USD Million)
12.3.3. Givlaari®
12.3.3.1. Sales Forecast (USD Million)
12.3.4. Oxlumo®
12.3.4.1. Sales Forecast (USD Million)
12.3.5. Leqvio®
12.3.5.1. Sales Forecast (USD Million)
12.3.6. Amvuttra®
12.3.6.1. Sales Forecast (USD Million)
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
LIST OF FIGURES
Figure 3.1. Key Historical Events
Figure 3.2. Structure of Next Generation Drug Conjugates
Figure 3.3. Biochemical Interaction and Mechanism of Action
Figure 3.4. Key Target Indications
Figure 4.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Figure 4.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Figure 4.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Figure 4.4. Next Generation Drug Conjugates: Distribution by Biological Target
Figure 4.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Figure 4.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Figure 4.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Figure 4.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Figure 4.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Figure 4.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Figure 4.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Figure 4.12. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Figure 4.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Figure 4.14. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.15. Next Generation Drug Conjugate Developers: Distribution by Company Size
Figure 4.16. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.18. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Figure 4.19. Most Active Players: Distribution by Number of Drug Candidates
Figure 6.1. Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Status
Figure 6.4. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 6.5. Clinical Trial Analysis: Distribution by Primary Purpose
Figure 6.6. Clinical Trial Analysis: Distribution by Age Group
Figure 6.7. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.8. Most Active Industry Players: Distribution by Number of Trials
Figure 6.9. Leading Drug Candidates: Distribution by Number of Trials
Figure 6.10. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Figure 6.11. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.12. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 6.13. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 6.14. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Figure 6.15. Clinical Trial Analysis: Distribution by Trial Status and Trial Location
Figure 7.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.7. Partnerships and Collaborations: Distribution by Type of Partner and Parent Company Size
Figure 7.8. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.9. Most Active Players: Distribution by Number of Partnerships
Figure 7.10. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Figure 7.11. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Figure 7.12. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1. Academic Grants Analysis: Distribution by Year of Grant Award
Figure 8.2. Academic Grants Analysis: Distribution by Amount Awarded
Figure 8.3. Academic Grants Analysis: Distribution by Funding Institute Center
Figure 8.4. Academic Grants Analysis: Distribution by Support Period
Figure 8.5. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6. Academic Grants Analysis: Distribution by Type of Grant Application
Figure 8.7. Academic Grants Analysis: Distribution by Purpose of Grant
Figure 8.8. Academic Grants Analysis: Distribution by Activity Code
Figure 8.9. Academic Grants Analysis: Distribution by Study Section
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.11 Academic Grants Analysis: Distribution by Type of Recipient Organization
Figure 8.12. Popular Recipient Organization: Distribution by Number of Grants
Figure 8.13. Popular Recipient Organization: Distribution by Amount Awarded
Figure 8.14 Prominent Program Officers: Distribution by Number of Grants
Figure 8.15. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Figure 9.1. Publication Analysis: Distribution by Year of Publication
Figure 9.2. Publication Analysis: Distribution by Type of Publication
Figure 9.3. Publication Analysis: Distribution by Type of Conjugate
Figure 9.4. Publication Analysis: Distribution by Target Indication
Figure 9.5. Publication Analysis: Distribution by Copyright Holder
Figure 9.6. Word Cloud: Emerging Focus Area
Figure 9.7. Most Active Publishers: Distribution by Number of Publications
Figure 9.8. Key Journals: Distribution by Number of Publications
Figure 9.9. Key Journals: Distribution by Impact Factor
Figure 10.1. Drug Failure Analysis: Distribution by Status of Discontinuation
Figure 10.2. Drug Failure Analysis: Distribution by Phase of Discontinuation
Figure 10.3. Drug Failure Analysis: Distribution by Average Trial Year
Figure 10.4. Drug Failure Analysis: Distribution by Type of Therapy
Figure 10.5. Drug Failure Analysis: Distribution by Target Indication
Figure 10.6. Drug Failure Analysis: Distribution by Reason for Drug Failure
Figure 11.1. Success Protocol Analysis: Lutathera® (Gastroenteropancreatic Neuroendocrine Tumor)
Figure 11.2. Success Protocol Analysis: Pluvicto® (Prostate Cancer)
Figure 11.3. Success Protocol Analysis: Givlaari® (Acute Hepatic Porphyria)
Figure 11.4 Success Protocol Analysis: Oxlumo® (Primary Hyperoxaluria)
Figure 11.5 Success Protocol Analysis: Amvuttra® (Hereditary ATTR Amyloidosis)
Figure 11.6 Success Protocol Analysis: Leqvio® (Heterozygous Familial Hypercholesterolemia)
Figure 11.7 Harvey ball Analysis: Overall Assessment of Approved Next Generation Drug Conjugates
Figure 12.1. Global Next Generation Drug Conjugates Market, 2022-2035 (USD Million), Base Scenario
Figure 12.2. Global Next Generation Drug Conjugates Market, 2022-2035 (USD Million), Conservative Scenario
Figure 12.3. Global Next Generation Drug Conjugates Market, 2022-2035 (USD Million), Optimistic Scenario
Figure 12.4. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2022-2035 (USD Million)
Figure 12.5. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2022-2035 (USD Million)
Figure 12.6 Next Generation Drug Conjugates Market for Ligand mediated RNAi Conjugates, 2022-2035 (USD Million)
Figure 12.7. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2022-2035 (USD Million)
Figure 12.8. Next Generation Drug Conjugates Market for Amino Sugars, 2022-2035 (USD Million)
Figure 12.9 Next Generation Drug Conjugates Market for Peptides, 2022-2035 (USD Million)
Figure 12.10. Next Generation Drug Conjugates Market for Lipids, 2022-2035 (USD Million)
Figure 12.11. Next Generation Drug Conjugates Market for Radionuclides, 2022-2035 (USD Million)
Figure 12.12. Next Generation Drug Conjugates Market for Drugs, 2022-2035 (USD Million)
Figure 12.13. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2022-2035 (USD Million)
Figure 12.14. Next Generation Drug Conjugates Market for si-RNAs, 2022-2035 (USD Million)
Figure 12.15 Next Generation Drug Conjugates Market for Monotherapy, 2022-2035 (USD Million)
Figure 12.16. Next Generation Drug Conjugates Market for Combination Therapy 2022-2035 (USD Million)
Figure 12.17. Next Generation Intravenous Drug Conjugates Market, 2022-2035 (USD Million)
Figure 12.18. Next Generation Subcutaneous Drug Conjugates Market, 2022-2035 (USD Million)
Figure 12.19. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035 (USD Million)
Figure 12.20. Next Generation Drug Conjugates Market for Prostate Cancer, 2022-2035 (USD Million)
Figure 12.21. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2022-2035 (USD Million)
Figure 12.22. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2022-2035 (USD Million)
Figure 12.23. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2022-2035 (USD Million)
Figure 12.24. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
Figure 12.25. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, 2022-2035 (USD Million)
Figure 12.26. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2022-2035 (USD Million)
Figure 12.27. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2022-2035 (USD Million)
Figure 12.28. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2022-2035 (USD Million)
Figure 12.29. Next Generation Drug Conjugates Market for Hemophilia, 2022-2035 (USD Million)
Figure 12.30. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2022-2035 (USD Million)
Figure 12.31. Next Generation Drug Conjugates Market for Myelofibrosis, 2022-2035 (USD Million)
Figure 12.32. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2022-2035 (USD Million)
Figure 12.33. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2022-2035 (USD Million)
Figure 12.34. Next Generation Drug Conjugates Market for Cardiovascular Diseases due to HLP, 2022-2035 (USD Million)
Figure 12.35. Next Generation Drug Conjugates Market in North America, 2022-2035 (USD Million)
Figure 12.36. Next Generation Drug Conjugates Market in the US, 2022-2035 (USD Million)
Figure 12.37. Next Generation Drug Conjugates Market in Canada, 2022-2035 (USD Million)
Figure 12.38. Next Generation Drug Conjugates Market in Europe, 2022-2035 (USD Million)
Figure 12.39. Next Generation Drug Conjugates Market in France, 2022-2035 (USD Million)
Figure 12.40. Next Generation Drug Conjugates Market in the UK, 2022-2035 (USD Million)
Figure 12.41. Next Generation Drug Conjugates Market in Germany, 2022-2035 (USD Million)
Figure 12.42. Next Generation Drug Conjugates Market in Italy, 2022-2035 (USD Million)
Figure 12.43. Next Generation Drug Conjugates Market in Spain, 2022-2035 (USD Million)
Figure 12.44. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035 (USD Million)
Figure 12.45. Next Generation Drug Conjugates Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 12.46. Next Generation Drug Conjugates Market in Japan, 2022-2035 (USD Million)
Figure 12.47. Next Generation Drug Conjugates Market in Brazil, 2022-2035 (USD Million)
Figure 12.48. Next Generation Drug Conjugates Market in Australia, 2022-2035 (USD Million)
Figure 12.49. Next Generation Drug Conjugates Market in Rest of the World, 2022-2035 (USD Million)
Figure 12.50. Lutathera®: Sales Forecast (USD Million)
Figure 12.51. Pluvicto®: Sales Forecast (USD Million)
Figure 12.52. Givlaari®: Sales Forecast (USD Million)
Figure 12.53. Oxlumo®: Sales Forecast (USD Million)
Figure 12.54. Leqvio®: Sales Forecast (USD Million)
Figure 12.55. Amvuttra®: Sales Forecast (USD Million)
Figure 12.56. Eplontersen: Sales Forecast (USD Million)
Figure 12.57. Olezarsen: Sales Forecast (USD Million)
Figure 12.58. Pelacarsen: Sales Forecast (USD Million)
Figure 12.59. Donidalorsen: Sales Forecast (USD Million)
Figure 12.60. Fitusiran: Sales Forecast (USD Million)
Figure 12.61. Nedosiran: Sales Forecast (USD Million)
Figure 12.62. Imetlestat: Sales Forecast (USD Million)
Figure 12.63. Olpasiran: Sales Forecast (USD Million)
Figure 12.64. ARO-AAT: Sales Forecast (USD Million)
Figure 12.65. ARO-APOC3: Sales Forecast (USD Million)
Figure 12.66. ANG-1005: Sales Forecast (USD Million)
LIST OF TABLES
Table 4.1. Next Generation Drug Conjugates: Therapy Pipeline
Table 4.2. Next Generation Drug Conjugates: List of Developers
Table 5.1. Advance Accelerator Applications: Product Portfolio
Table 5.2. Lutathera®: Drug Overview
Table 5.3. Lutathera®: Clinical Trial Information
Table 5.4 Lutathera®: Dosing Regimen
Table 5.5 Pluvicto®: Drug Overview
Table 5.6 Pluvicto®: Clinical Trial Information
Table 5.7 Pluvicto®: Dosing Regimen
Table 5.8 Advance Accelerator Applications: Recent Developments and Future Outlook
Table 5.9. Alnylam Pharmaceuticals: Product Portfolio
Table 5.10. Givlaari®: Drug Overview
Table 5.11. Givlaari®: Clinical Trial Information
Table 5.12 Givlaari®: Dosing Regimen
Table 5.13. Oxlumo®: Drug Overview
Table 5.14. Oxlumo®: Clinical Trial Information
Table 5.15 Oxlumo®: Dosing Regimen
Table 5.16. Leqvio®: Drug Overview
Table 5.17. Leqvio®: Clinical Trial Information
Table 5.18. Leqvio®: Dosing Regimen
Table 5.19. Amvuttra®: Drug Overview
Table 5.20. Amvuttra®: Clinical Trial Information
Table 5.21. Amvuttra®: Dosing Regimen
Table 5.22. Alnylam Pharmaceuticals: Recent Developments and Future Outlook
Table 5.23. Arrowhead Pharmaceuticals: Product Portfolio
Table 5.24. Olapsiran: Drug Overview
Table 5.25. Olpasiran: Clinical Trial Information
Table 5.26 Olapsiran: Dosing Regimen
Table 5.27. ARO-AAT: Drug Overview
Table 5.28. ARO-AAT: Clinical Trial Information
Table 5.29 ARO-AAT: Dosing Regimen
Table 5.30. ARO-APOC3: Drug Overview
Table 5.31. ARO-APOC3: Clinical Trial Information
Table 5.32 ARO-APOC3: Dosing Regimen
Table 5.33. Arrowhead Pharmaceuticals: Recent Developments and Future Outlook
Table 5.34. Dicerna Pharmaceuticals: Product Portfolio
Table 5.35. Nedosiran: Drug Overview
Table 5.36. Nedosiran: Clinical Trial Information
Table 5.37 Nedosiran: Dosing Regimen
Table 5.38. Dicerna Pharmaceuticals: Recent Developments and Future Outlook
Table 5.39. Geron: Product Portfolio
Table 5.40. Imtelstat: Drug Overview
Table 5.41. Imtelstat: Clinical Trial Information
Table 5.42 Imtelstat: Dosing Regimen
Table 5.43. Geron: Recent Developments and Future Outlook
Table 5.44. Ionis Pharmaceuticals: Product Portfolio
Table 5.45. Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Drug Overview
Table 5.46. Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Clinical Trial Information
Table 5.47 Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Dosing Regimen
Table 5.48. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Drug Overview
Table 5.49. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Clinical Trial Information
Table 5.50. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Dosing Regimen
Table 5.51. Olezarsen: Drug Overview
Table 5.52. Olezarsen: Clinical Trial Information
Table 5.53. Olezarsen: Dosing Regimen
Table 5.54. Pelacarsen: Drug Overview
Table 5.55. Pelacarsen: Clinical Trial Information
Table 5.56. Pelacarsen: Dosing Regimen
Table 5.57. Donidalorsen: Drug Overview
Table 5.58. Donidalorsen: Clinical Trial Information
Table 5.59. Donidalorsen: Dosing Regimen
Table 5.60. Ionis Pharmaceuticals: Recent Developments and Future Outlook
Table 6.1. Next Generation Drug Conjugates: List of Clinical Trials (Sample Data, Pre-2017-2023)
Table 7.1. Next Generation Drug Conjugates: List of Partnerships and Collaborations (2018-2023)
Table 8.1. Next Generation Drug Conjugates: List of Academic Grants (Sample Data, Pre-2021-2023)
Table 9.1. Next Generation Drug Conjugates: List of Publications (Sample Data, 2018-2023)
Table 10.1. Next Generation Drug Conjugates: List of Failed Drugs
Table 12.1. Next Generation Drug Conjugates Market: List of Forecasted Drugs
Table 13.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Table 13.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Table 13.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Table 13.4. Next Generation Drug Conjugates: Distribution by Biological Target
Table 13.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Table 13.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Table 13.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Table 13.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Table 13.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Table 13.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Table 13.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Table 13.12. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Table 13.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Table 13.14. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Table 13.15. Next Generation Drug Conjugate Developers: Distribution by Company Size
Table 13.16. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Table 13.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Table 13.18. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Table 13.19. Most Active Players: Distribution by Number of Drug Candidates
Table 13.20. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.21. Clinical Trial Analysis: Distribution by Trial Phase
Table 13.22. Clinical Trial Analysis: Distribution by Trial Status
Table 13.23. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.24. Clinical Trial Analysis: Distribution by Primary Purpose
Table 13.25. Clinical Trial Analysis: Distribution by Patient Age Group
Table 13.26. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.27. Most Active Industry Players: Distribution by Number of Trials
Table 13.28. Leading Drug Candidates: Distribution by Number of Trials
Table 13.29. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Table 13.30. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 13.31. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 13.32. Clinical Trial Analysis: Distribution by Trial Status and Trial Registration Year
Table 13.33. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Table 13.34. Clinical Trial Analysis: Distribution by Trial Phase and Trial Location
Table 13.35. Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.36. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.37. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.38. Partnerships and Collaborations: Distribution by Type of Partner
Table 13.39. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.40. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.41. Partnerships and Collaborations: Distribution by Parent Company Size and Type of Partner
Table 13.42. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.43. Most Active Players: Analysis by Number of Partnerships
Table 13.44. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Table 13.45. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Table 13.46. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.47. Academic Grants Analysis: Distribution by Year of Grant Award
Table 13.48. Academic Grants Analysis: Distribution by Amount Awarded
Table 13.49 Academic Grants Analysis: Distribution by Funding Institute Center
Table 13.50. Academic Grants Analysis: Distribution by Support Period
Table 13.51. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 13.52. Academic Grants Analysis: Distribution by Type of Grant Application
Table 13.53. Academic Grants Analysis: Distribution by Purpose of Grant
Table 13.54. Academic Grants Analysis: Distribution by Activity Code
Table 13.55. Academic Grants Analysis: Distribution by Study Section
Table 13.56 Popular NIH Departments: Distribution by Number of Grants
Table 13.57 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 13.58. Popular Recipient Organizations: Distribution by Number of Grants
Table 13.59. Popular Recipient Organizations: Distribution by Amount Awarded
Table 13.60 Prominent Program Officers: Analysis by Number of Grants
Table 13.61. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Table 13.62. Publication Analysis: Distribution by Year of Publication
Table 13.63. Publication Analysis: Distribution by Type of Publication
Table 13.64. Publication Analysis: Distribution by Type of Conjugate
Table 13.65. Publication Analysis: Distribution by Target Indication
Table 13.66. Publication Analysis: Distribution by Copyright Holder
Table 13.67. Word Cloud: Emerging Focus Area
Table 13.68. Most Active Publishers: Distribution by Number of Publications
Table 13.69. Key Journals: Distribution by Number of Publications
Table 13.70. Key Journals: Distribution by Impact Factor
Table 13.71. Drug Failure Analysis: Distribution by Status of Discontinuation
Table 13.72. Drug Failure Analysis: Distribution by Phase of Discontinuation
Table 13.73. Drug Failure Analysis: Distribution by Average Trial Year
Table 13.74. Drug Failure Analysis: Distribution by Type of Therapy
Table 13.75. Drug Failure Analysis: Distribution by Target Indication
Table 13.76 Drug Failure Analysis: Distribution by Reason of Drug Failure
Table 13.77. Global Next Generation Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.78. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.79. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.80. Next Generation Drug Conjugates: Distribution for Ligand mediated RNAi Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.81. Next Generation Drug Conjugates Market for by Peptide Drug Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.82. Next Generation Drug Conjugates Market: Distribution for Amino Sugars, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.83. Next Generation Drug Conjugates Market for Peptides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.84. Next Generation Drug Conjugates Market for Lipids, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.85. Next Generation Drug Conjugates Market for Radionuclides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.86. Next Generation Drug Conjugates Market for Drugs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.87. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.88. Next Generation Drug Conjugates Market for si-RNAs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.89. Next Generation Drug Conjugates Market for Monotherapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.90. Next Generation Drug Conjugates Market for Combination Therapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.91. Next Generation Intravenous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.92. Next Generation Subcutaneous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.93. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.94. Next Generation Drug Conjugates Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.95. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.96. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.97. Next Generation Drug Conjugates Market for Primary Hyperoxaluria , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.98. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.99. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.100. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.101. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.102. Next Generation Drug Conjugates Market for Hereditary Angioedema, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.103. Next Generation Drug Conjugates Market for Hemophilia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.104. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.105. Next Generation Drug Conjugates Market for Myelofibrosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.106. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.107. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.108. Next Generation Drug Conjugates Market for Cardiovascular Diseases complications due to Hyperlipoproteinemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.109. Next Generation Drug Conjugates Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.110. Next Generation Drug Conjugates Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.111. Next Generation Drug Conjugates Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.112. Next Generation Drug Conjugates Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.113. Next Generation Drug Conjugates Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.114. Next Generation Drug Conjugates Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.115. Next Generation Drug Conjugates Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.116. Next Generation Drug Conjugates Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.117. Next Generation Drug Conjugates Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.118. Next Generation Drug Conjugates Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.119. Next Generation Drug Conjugates Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.120. Next Generation Drug Conjugates Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.121. Next Generation Drug Conjugates Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.122. Next Generation Drug Conjugates Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.123. Next Generation Drug Conjugates Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.124. Lutathera®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.125. Pluvicto®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.126. Givlaari®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.127. Oxlumo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.128. Leqvio®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.129. Amvuttra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.130. Eplontersen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.131. Olezarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.132. Pelacarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.133. Donidalorsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.134. Fitusiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.135. Nedosiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.136. Imetlestat: Sales Forecast, Conservative, Base and Optimistic Scenarios, 20232035 (USD Million)
Table 13.137. Olpasiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.138. ARO-AAT: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.139. ARO-APOC3: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.140. ANG-1005: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
